Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 14/20 | 0.58 |
| ▸ | DRD2 | P14416 | 13/20 | 0.58 |
| ▸ | HTR2A | P28223 | 13/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5375318 | 0.88 | HTR1A (0.55) | HTR1ADRD2HTR2AKCNH2SLC6A4 | |
| SCHEMBL5363521 | 0.85 | DRD2 (0.62) | HTR1ADRD2HTR2AKCNH2DRD3 | |
| SCHEMBL21239146 | 0.84 | HTR1A (0.57) | HTR1ADRD2HTR2AKCNH2SLC6A4 | |
| SCHEMBL21239014 | 0.84 | HTR1A (0.57) | HTR1ADRD2HTR2AKCNH2SLC6A4 | |
| SCHEMBL5369461 | 0.82 | DRD2 (0.51) | HTR1ADRD2HTR2ASLC6A4DRD3 | |
| SCHEMBL15534212 | 0.78 | HTR1A (0.59) | HTR1ADRD2HTR2AKCNH2SLC6A4 | |
| SCHEMBL15601661 | 0.78 | DRD2 (0.62) | HTR1ADRD2HTR2AKCNH2SLC6A4 | |
| SCHEMBL17471492 | 0.78 | DRD2 (0.59) | HTR1ADRD2HTR2AKCNH2SLC6A4 | |
| SCHEMBL16559710 | 0.78 | HTR1A (0.61) | HTR1ADRD2HTR2AKCNH2SLC6A4 | |
| SCHEMBL5827507 | 0.77 | DRD2 (0.51) | HTR1ADRD2HTR2AKCNH2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160888-B2 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT COMPANY LLC (US) | 2007-01-09 | — | — | US | disclosed |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| EP-1660497-A1 | [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | DRD1, DRD2, DRD3 | HTR1A 191/4885DRD2 2/4885HTR2A 328/4885 |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | HTR1A 191/4885DRD2 2/4885HTR2A 328/4885 |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | HTR1A 191/4885DRD2 2/4885HTR2A 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.